Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation on Q2FY24 Financial Results06-11-2023
06-11-2023
Gland Pharma Ltd - 543245 - Unaudited Financial Results Of The Company For The Quarter And Half Year Ended September 30, 2023
Unaudited financial results of the Company for the quarter and half year ended September 30, 202306-11-2023
Gland Pharma Ltd - 543245 - Board Meeting Outcome for Board Meeting Outcome For Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2023
The Board of Directors at its meeting held on November 06, 2023 has inter-alia approved the Unaudited financial results of the Company for the quarter and half year ended September 30, 202306-11-2023
Gland Pharma Ltd - 543245 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Lakumi Trust28-10-2023
Gland Pharma Ltd - 543245 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nilay Discretionary Trust28-10-2023
Gland Pharma Ltd - 543245 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Empower Discretionary Trust28-10-2023
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publication20-10-2023
Gland Pharma Ltd - 543245 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Notice of the Postal Ballot19-10-2023
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publication18-10-2023
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Earnings Conference Call - Q2FY2417-10-2023